TGR5 and Immunometabolism: Insights from Physiology and Pharmacology

Paragh, 2014, Dynamic interplay between metabolic syndrome and immunity, Adv. Exp. Med. Biol., 824, 171, 10.1007/978-3-319-07320-0_13 Olefsky, 2010, Macrophages, inflammation, and insulin resistance, Annu. Rev. Physiol., 72, 219, 10.1146/annurev-physiol-021909-135846 Lionetti, 2009, From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation, Nutr. Metab. Cardiovasc. Dis., 19, 146, 10.1016/j.numecd.2008.10.010 Reid, 1957, Aspirin and diabetes mellitus, Br. Med. J., 2, 1071, 10.1136/bmj.2.5053.1071 Spranger, 2003, Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study, Diabetes, 52, 812, 10.2337/diabetes.52.3.812 Lontchi-Yimagou, 2013, Diabetes mellitus and inflammation, Curr. Diab. Rep., 13, 435, 10.1007/s11892-013-0375-y Lumeng, 2011, Inflammatory links between obesity and metabolic disease, J. Clin. Invest., 121, 2111, 10.1172/JCI57132 Cildir, 2013, Chronic adipose tissue inflammation: all immune cells on the stage, Trends Mol. Med., 19, 487, 10.1016/j.molmed.2013.05.001 Thomas, 2008, Targeting bile-acid signalling for metabolic diseases, Nat. Rev. Drug Discov., 7, 678, 10.1038/nrd2619 Russell, 2009, Fifty years of advances in bile acid synthesis and metabolism, J. Lipid Res., 50, S120, 10.1194/jlr.R800026-JLR200 Dawson, 2015, Intestinal transport and metabolism of bile acids, J. Lipid Res., 56, 1085, 10.1194/jlr.R054114 Matsubara, 2013, FXR signaling in the enterohepatic system, Mol. Cell. Endocrinol., 368, 17, 10.1016/j.mce.2012.05.004 Houten, 2006, Endocrine functions of bile acids, EMBO J., 25, 1419, 10.1038/sj.emboj.7601049 Shaham, 2008, Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity, Mol. Syst. Biol., 4, 214, 10.1038/msb.2008.50 Duboc, 2014, The bile acid TGR5 membrane receptor: from basic research to clinical application, Dig. Liver Dis., 46, 302, 10.1016/j.dld.2013.10.021 Hench, 1938, Effect of jaundice on rheumatoid arthritis, Br. Med. J., 2, 394, 10.1136/bmj.2.4050.394 Gadaleta, 2015, Tissue-specific actions of FXR in metabolism and cancer, Biochim. Biophys. Acta, 1851, 30, 10.1016/j.bbalip.2014.08.005 Hageman, 2010, A role of the bile salt receptor FXR in atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 30, 1519, 10.1161/ATVBAHA.109.197897 Kawamata, 2003, A G protein-coupled receptor responsive to bile acids, J. Biol. Chem., 278, 9435, 10.1074/jbc.M209706200 Maruyama, 2002, Identification of membrane-type receptor for bile acids (M-BAR), Biochem. Biophys. Res. Commun., 298, 714, 10.1016/S0006-291X(02)02550-0 Macchiarulo, 2013, Probing the binding site of bile acids in TGR5, ACS Med. Chem. Lett., 4, 1158, 10.1021/ml400247k Hov, 2010, Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis, PLoS ONE, 5, e12403, 10.1371/journal.pone.0012403 Watanabe, 2006, Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation, Nature, 439, 484, 10.1038/nature04330 Harach, 2012, TGR5 potentiates GLP-1 secretion in response to anionic exchange resins, Sci. Rep., 2, 430, 10.1038/srep00430 Kumar, 2012, Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells, Biochem. Biophys. Res. Commun., 427, 600, 10.1016/j.bbrc.2012.09.104 Potthoff, 2013, Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice, Am. J. Physiol. Gastrointest. Liver Physiol., 304, G371, 10.1152/ajpgi.00400.2012 Thomas, 2009, TGR5-mediated bile acid sensing controls glucose homeostasis, Cell Metab., 10, 167, 10.1016/j.cmet.2009.08.001 Vassileva, 2010, Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice, J. Endocrinol., 205, 225, 10.1677/JOE-10-0009 Keitel, 2009, The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders, Hepatology, 50, 861, 10.1002/hep.23032 Keitel, 2010, The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes, Biol. Chem., 391, 785, 10.1515/bc.2010.077 Lavoie, 2010, Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels, J. Physiol., 588, 3295, 10.1113/jphysiol.2010.192146 Li, 2011, The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling, Mol. Endocrinol., 25, 1066, 10.1210/me.2010-0460 Masyuk, 2013, Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling, Am. J. Physiol. Gastrointest. Liver Physiol., 304, G1013, 10.1152/ajpgi.00383.2012 Pean, 2013, The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice, Hepatology, 58, 1451, 10.1002/hep.26463 Alemi, 2013, The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice, Gastroenterology, 144, 145, 10.1053/j.gastro.2012.09.055 Poole, 2010, Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system, Neurogastroenterol. Motil., 22, 814, 10.1111/j.1365-2982.2010.01487.x Ward, 2013, The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon, Neurogastroenterol. Motil., 25, 708, 10.1111/nmo.12148 Alemi, 2013, The TGR5 receptor mediates bile acid-induced itch and analgesia, J. Clin. Invest., 123, 1513, 10.1172/JCI64551 Keitel, 2008, Expression and function of the bile acid receptor TGR5 in Kupffer cells, Biochem. Biophys. Res. Commun., 372, 78, 10.1016/j.bbrc.2008.04.171 Lumeng, 2007, Obesity induces a phenotypic switch in adipose tissue macrophage polarization, J. Clin. Invest., 117, 175, 10.1172/JCI29881 Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J. Clin. Invest., 112, 1796, 10.1172/JCI200319246 Xu, 2003, Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J. Clin. Invest., 112, 1821, 10.1172/JCI200319451 McNelis, 2014, Macrophages, immunity, and metabolic disease, Immunity, 41, 36, 10.1016/j.immuni.2014.05.010 Solinas, 2010, JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction, FASEB J., 24, 2596, 10.1096/fj.09-151340 Nguyen, 2007, A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways, J. Biol. Chem., 282, 35279, 10.1074/jbc.M706762200 Chawla, 2011, Macrophage-mediated inflammation in metabolic disease, Nat. Rev. Immunol., 11, 738, 10.1038/nri3071 Odegaard, 2013, Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis, Science, 339, 172, 10.1126/science.1230721 Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol., 8, 958, 10.1038/nri2448 Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034 Lumeng, 2008, Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes, Diabetes, 57, 3239, 10.2337/db08-0872 Lumeng, 2007, Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity, Diabetes, 56, 16, 10.2337/db06-1076 Wu, 2011, Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis, Science, 332, 243, 10.1126/science.1201475 Perino, 2014, TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation, J. Clin. Invest., 124, 5424, 10.1172/JCI76289 Rocha, 2009, Obesity, inflammation, and atherosclerosis, Nat. Rev. Cardiol., 6, 399, 10.1038/nrcardio.2009.55 Chinetti-Gbaguidi, 2015, Macrophage subsets in atherosclerosis, Nat. Rev. Cardiol., 12, 10, 10.1038/nrcardio.2014.173 Pols, 2011, TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading, Cell Metab., 14, 747, 10.1016/j.cmet.2011.11.006 Miyazaki-Anzai, 2014, Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis, PLoS ONE, 9, e108270, 10.1371/journal.pone.0108270 Baffy, 2009, Kupffer cells in non-alcoholic fatty liver disease: the emerging view, J. Hepatol., 51, 212, 10.1016/j.jhep.2009.03.008 McMahan, 2013, Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease, J. Biol. Chem., 288, 11761, 10.1074/jbc.M112.446575 Wang, 2011, The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in mice, Hepatology, 54, 1421, 10.1002/hep.24525 Smythies, 2005, Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity, J. Clin. Invest., 115, 66, 10.1172/JCI200519229 Abraham, 2009, Inflammatory bowel disease, N. Engl. J. Med., 361, 2066, 10.1056/NEJMra0804647 Cipriani, 2011, The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis, PLoS ONE, 6, e25637, 10.1371/journal.pone.0025637 Yoneno, 2013, TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease, Immunology, 139, 19, 10.1111/imm.12045 Lee, 2014, Gut microbiota-generated metabolites in animal health and disease, Nat. Chem. Biol., 10, 416, 10.1038/nchembio.1535 Boesjes, 2014, Metabolic effects of bile acids in the gut in health and disease, Curr. Med. Chem., 21, 2822, 10.2174/0929867321666140303142053 Buffie, 2015, Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile, Nature, 517, 205, 10.1038/nature13828 Sayin, 2013, Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist, Cell Metab., 17, 225, 10.1016/j.cmet.2013.01.003 Theriot, 2014, Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection, Nat. Commun., 5, 3114, 10.1038/ncomms4114 Seeley, 2015, The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes, Cell Metab., 21, 369, 10.1016/j.cmet.2015.01.001 Fang, 2015, Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance, Nat. Med., 21, 159, 10.1038/nm.3760 Pellicciari, 2007, Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5, J. Med. Chem., 50, 4265, 10.1021/jm070633p Sato, 2008, Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure–activity relationships, and molecular modeling studies, J. Med. Chem., 51, 1831, 10.1021/jm7015864 Pellicciari, 2009, Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity, J. Med. Chem., 52, 7958, 10.1021/jm901390p Sato, 2007, Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea, Biochem. Biophys. Res. Commun., 362, 793, 10.1016/j.bbrc.2007.06.130 Genet, 2010, Structure–activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes, J. Med. Chem., 53, 178, 10.1021/jm900872z Genet, 2010, Redefining the TGR5 triterpenoid binding pocket at the C-3 position, ChemMedChem, 5, 1983, 10.1002/cmdc.201000329 Ichikawa, 2012, Bile acids induce monocyte differentiation toward interleukin-12 hypo-producing dendritic cells via a TGR5-dependent pathway, Immunology, 136, 153, 10.1111/j.1365-2567.2012.03554.x Haselow, 2013, Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages, J. Leukoc. Biol., 94, 1253, 10.1189/jlb.0812396 Mobraten, 2014, Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line, J. Recept. Signal Transduct. Res., 24, 1 Lou, 2014, GPBAR1/TGR5 mediates bile acid-induced cytokine expression in murine Kupffer cells, PLoS ONE, 9, e93567, 10.1371/journal.pone.0093567 Gioiello, 2012, Pat-ented TGR5 modulators: a review (2006 – present), Expert Opin. Ther. Pat., 22, 1399, 10.1517/13543776.2012.733000 Stepanov, 2013, The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders, J. Recept. Signal Transduct. Res., 33, 213, 10.3109/10799893.2013.802805 Zhong, 2010, TGR5 as a therapeutic target for treating obesity, Curr. Top. Med. Chem., 10, 386, 10.2174/156802610790980576 Tiwari, 2009, TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders, Drug Discov. Today, 14, 523, 10.1016/j.drudis.2009.02.005 Sepe, 2014, Modification on ursodeoxycholic acid (UDCA) scaffold, Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1), J. Med. Chem., 57, 7687, 10.1021/jm500889f Park, 2014, Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists, Bioorg. Med. Chem. Lett., 24, 4271, 10.1016/j.bmcl.2014.07.026 Phillips, 2014, Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy, J. Med. Chem., 57, 3263, 10.1021/jm401731q Zambad, 2013, TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity, Diabetes Metab. Syndr. Obes., 7, 1, 10.2147/DMSO.S50209 Londregan, 2013, Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries, Bioorg. Med. Chem. Lett., 23, 1407, 10.1016/j.bmcl.2012.12.076 Piotrowski, 2013, Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists, ACS Med. Chem. Lett., 4, 63, 10.1021/ml300277t Herbert, 2010, Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5, Bioorg. Med. Chem. Lett., 20, 5718, 10.1016/j.bmcl.2010.08.014 Evans, 2009, Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists, J. Med. Chem., 52, 7962, 10.1021/jm901434t Budzik, 2010, Synthesis and structure–activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists, Bioorg. Med. Chem. Lett., 20, 1363, 10.1016/j.bmcl.2010.01.003 Dehmlow, 2013, Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists, Bioorg. Med. Chem. Lett., 23, 4627, 10.1016/j.bmcl.2013.06.017 Duan, 2012, Design, synthesis and anti-diabetic activity of 4-phenoxy-nicotinamide and 4-phenoxy-pyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists, J. Med. Chem., 55, 10475, 10.1021/jm301071h Martin, 2013, 2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5), ChemMedChem, 8, 569, 10.1002/cmdc.201200474 Swann, 2011, Systemic gut microbial modulation of bile acid metabolism in host tissue compartments, Proc. Natl. Acad. Sci. U.S.A., 108, 4523, 10.1073/pnas.1006734107 Zhu, 2013, Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold, Eur. J. Med. Chem., 69, 55, 10.1016/j.ejmech.2013.07.050 Zhu, 2013, Design, synthesis, and structure–activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists, ChemMedChem, 8, 1210, 10.1002/cmdc.201300144 Zou, 2014, 4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists, Eur. J. Med. Chem., 82, 1, 10.1016/j.ejmech.2014.05.031